Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

About this update from Lexicon Pharmaceuticals, Inc.

THE WOODLANDS, Texas - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments. 'Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,' said Mike Exton, Ph.D., Lexicon's chief executive officer and director. 'Among all the accomplishments, I'm particularly pleased that we have completed enrollment of our SONATA-HCM study on time, reflecting strong clinical interest for a novel class of medicine to treat HCM. Overall, I could not be more confident in how these opportunities are poised to shape the company over the coming months.' 'We remain very focused on disciplined, targeted capital allocation as we continue to advance our clinical programs,' said Scott Coiante, Lexicon's chief financial officer. 'With early commercial planning now underway for our late-state pipeline, we are committed to maximizing the value of these opportunities to create long-term shareholder value.' Second Quarter 2026 Business and Pipeline Highlights Cardiometabolic Sotagliflozin Sotagliflozin is a unique oral inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) and has been studied in approximately 20,000 patients across multiple cardiometabolic indications. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFA. Hypertrophic Cardiomyopathy (HCM) Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study, substantially exceeding its enrollment target of 500 patients across both non-obstructive (nHCM) or obstructive HCM (oHCM). The primary efficacy endpoint will assess improvement in symptoms for the entire population (nHCM and oHCM). The final study population included a substantial majority of patients with nHCM, providing a robust opportunity to evaluate sotagliflozin in a patient group for whom effective treatment options remain limited, as well as a meaningful cohort of patients with oHCM. Lexicon continues to expect topline results in the first quarter of 2027. Type 1 Diabetes (T1D) (ZYNQUISTA) Lexicon remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a patient population for which there are no treatment options b...

View stock analysis, news, and events for Lexicon Pharmaceuticals, Inc.